Increased monocyte-to-HDL cholesterol ratio is related to cardiac syndrome X

Adnan Dogan1, Muhammed Oylumlu1

  • 1a Department of Cardiology , Dumlupinar University School of Medicine , Kutahya , Turkey.

Acta Cardiologica
|August 31, 2017
PubMed

Insights

Cardiac Syndrome X (CSX) is linked to a higher monocyte-to-HDL cholesterol ratio (MHR), an inflammation marker. This new marker may aid in predicting CSX, offering a cost-effective addition to existing methods.

Area of Science:

  • Cardiology
  • Biomarkers
  • Inflammation

Background:

  • Cardiac Syndrome X (CSX) is characterized by angina-like chest pain and evidence of ischemia without coronary artery stenosis.
  • Current diagnostic methods for CSX include exercise tests and myocardial perfusion scintigraphy.
  • The role of inflammation in CSX pathogenesis is increasingly recognized.

Purpose of the Study:

  • To investigate the association between Cardiac Syndrome X (CSX) and the monocyte-to-HDL cholesterol ratio (MHR).
  • To evaluate MHR as a potential novel biomarker for CSX.
  • To explore the relationship between MHR and other hematological parameters in CSX patients.

Main Methods:

  • A study included 230 participants: 105 with CSX and 125 healthy controls.
  • Peripheral venous blood samples were collected before coronary angiography.
  • Monocyte-to-HDL cholesterol ratio (MHR) and other hematological parameters were measured.

Main Results:

  • Patients with CSX exhibited significantly higher monocyte counts and MHR compared to controls.
  • HDL-cholesterol levels were significantly lower in the CSX group.
  • Elevated MHR and plateletcrit (PCT) were independently associated with the presence of CSX.

Conclusions:

  • Elevated MHR is independently associated with the presence of Cardiac Syndrome X.
  • MHR may serve as a valuable, cost-effective biomarker for CSX prediction.
  • This finding suggests MHR can complement existing diagnostic approaches for CSX.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.3K
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
607
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
756
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
553
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
476
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
750